Literature DB >> 8950301

The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents.

A S Bourinbaiar1, E C Fruhstorfer.   

Abstract

The suppression of human immunodeficiency virus (HIV) replication by histamine type 2 (H2) receptor antagonists, cimetidine, ranitidine, and famotidine was examined in vitro. The 50% reduction (IC50) in p24 antigen expression caused by the anti-ulcer agent, cimetidine, was observed at 26.8 nM with IC100 at 10 microM. Unlike azidothymidine-a reverse transcriptase inhibitor-cimetidine blocked HIV infection without affecting cell growth, as no cytotoxicity was observed even at the highest 1 mM dose. Ranitidine and famotidine were less potent than cimetidine. H1 antagonists, cyproheptadine and diphenhydramine, had no effect on HIV replication. Although the activity of cimetidine was observed at concentrations attainable by oral administration, the mechanism of anti-HIV action is unknown. This is the first report on antiretroviral action of H2 blockers. Further studies are warranted to establish the potential of a new class of anti-HIV agents with immunomodulating properties.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950301     DOI: 10.1016/s0024-3205(96)00553-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  15 in total

Review 1.  Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges.

Authors:  Sarah Nadeem; Salima Saleem Aamdani; Bushra Ayub; Nashia Ali Rizvi; Fatima Safi Arslan; Russell Seth Martins; Maria Khan; Syed Faisal Mahmood
Journal:  Glob Health Epidemiol Genom       Date:  2022-04-20

2.  Repurposed GI Drugs in the Treatment of COVID-19.

Authors:  Enrik John T Aguila; Ian Homer Y Cua
Journal:  Dig Dis Sci       Date:  2020-06-29       Impact factor: 3.199

3.  Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis.

Authors:  Joseph T Ortega; Maria Luisa Serrano; Beata Jastrzebska
Journal:  Biomolecules       Date:  2020-06-24

4.  Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study.

Authors:  Daniel E Freedberg; Joseph Conigliaro; Timothy C Wang; Kevin J Tracey; Michael V Callahan; Julian A Abrams
Journal:  Gastroenterology       Date:  2020-05-22       Impact factor: 22.682

5.  Antiviral activity of Alpinia katsumadai extracts against rotaviruses.

Authors:  Ha-Hyun Kim; Hyung-Jun Kwon; Young Bae Ryu; Jong Sun Chang; Kyoung-Oh Cho; Myra D T Hosmillo; Mun-Chual Rho; Su-Jin Park; Woo Song Lee
Journal:  Res Vet Sci       Date:  2010-12-31       Impact factor: 2.534

6.  In vitro Antiviral Activity of Rubia cordifolia Aerial Part Extract against Rotavirus.

Authors:  Yuanyuan Sun; Xuepeng Gong; Jia Y Tan; Lifeng Kang; Dongyan Li; Jihong Yang; Guang Du
Journal:  Front Pharmacol       Date:  2016-09-13       Impact factor: 5.810

7.  Famotidine Against SARS-CoV2: A Hope or Hype?

Authors:  Ritwik Ghosh; Subhankar Chatterjee; Souvik Dubey; Carl J Lavie
Journal:  Mayo Clin Proc       Date:  2020-06-06       Impact factor: 7.616

8.  Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.

Authors:  Moshe Rogosnitzky; Esther Berkowitz; Alejandro R Jadad
Journal:  JMIR Public Health Surveill       Date:  2020-05-13

9.  Histamine receptors and COVID-19.

Authors:  Madeleine Ennis; Katerina Tiligada
Journal:  Inflamm Res       Date:  2020-11-18       Impact factor: 4.575

10.  Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.

Authors:  Jeffrey F Mather; Richard L Seip; Raymond G McKay
Journal:  Am J Gastroenterol       Date:  2020-10       Impact factor: 12.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.